LexAurum Advisors’s AbbVie ABBV Stock Holding History

LexAurum Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$740K	Buy	2,941 +537	+22%	+$116K	0.09%	187
2026 Q1	$523K	Buy	+2,404	New	+$533K	0.07%	219
2025 Q3	$567K	Buy	2,447 +657	+37%	+$134K	0.08%	185
2025 Q2	$332K	Buy	1,790 +154	+9%	+$28.6K	0.05%	256
2025 Q1	$343K	Sell	1,636 -73	-4%	-$14.2K	0.07%	242
2024 Q4	$304K	Buy	1,709 +549	+47%	+$101K	0.06%	261
2024 Q3	$229K	Buy	+1,160	New	+$216K	0.05%	278
2024 Q2	–	Sell	-1,152	Closed	-$210K	–	300
2024 Q1	$210K	Buy	+1,152	New	+$199K	0.05%	275
2021 Q4	–	Sell	-7,735	Closed	-$834K	–	251
2021 Q3	$834K	Buy	7,735 +138	+2%	+$15.8K	0.25%	98
2021 Q2	$856K	Buy	7,597 +440	+6%	+$49.6K	0.25%	97
2021 Q1	$775K	Buy	7,157 +196	+3%	+$21K	0.26%	89
2020 Q4	$746K	Buy	6,961 +2,237	+47%	+$215K	0.27%	92
2020 Q3	$414K	Buy	4,724 +691	+17%	+$65.1K	0.17%	122
2020 Q2	$396K	Buy	4,033 +552	+16%	+$48.6K	0.22%	102
2020 Q1	$265K	Buy	+3,481	New	+$297K	0.18%	125

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

LexAurum Advisors's ABBV Position: Q2 2026 in Review

LexAurum Advisors increased its AbbVie (ABBV) stake by 22% in Q2 2026, buying an estimated $116K and bringing the position to 2,941 shares worth $740K. The position accounts for 0.09% of the portfolio, ranked #187.

LexAurum Advisors first reported a position in ABBV in Q1 2020 and has held it in 15 quarters since. The position peaked at $856K in Q2 2021. 4,209 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

LexAurum Advisors held 2,941 shares of AbbVie worth $740K as of Q2 2026.
LexAurum Advisors bought 537 AbbVie shares in Q2 2026, an estimated $116K.
AbbVie made up 0.09% of LexAurum Advisors's portfolio in Q2 2026, its #187 holding.
LexAurum Advisors first reported a position in AbbVie in Q1 2020 and has held it in 15 quarters since.
LexAurum Advisors's AbbVie position peaked at $856K in Q2 2021.
4,209 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on LexAurum Advisors's 13F filing for Q2 2026, filed 15 Jul 2026.